30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
The Law Decree n. 9/2020 containing "urgent support measures for families, workers and businesses re...
Read More >
In today’s edition of Daily Compliance News: Trump wants cut of Microsoft TikTok deal. (WaPo) BP r...
Read More >
U.S. Citizenship and Immigration Services (USCIS) has made significant changes to the Immigrant Inve...
Read More >
On March 14, 2019 the Department of Labor issued an opinion letter considering whether employers vio...
Read More >
In bringing meal and rest period claims on behalf of their clients, the plaintiffs’ bar has long ar...
Read More >
Many of our clients have noticed that the Government is increasingly using accusations of contractor...
Read More >